SOMX Share Price

Open 2.95 Change Price %
High 3.00 1 Day 0.10 3.45
Low 2.91 1 Week 0.00 0.00
Close 3.00 1 Month 0.00 0.00
Volume 21834 1 Year 0.00 0.00
52 Week High 59.50
52 Week Low 0.00
SOMX Important Levels
Resistance 2 3.08
Resistance 1 3.05
Pivot 2.97
Support 1 2.95
Support 2 2.92
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
FB 115.10 -2.80%
MU 18.48 -5.38%
MU 18.48 -5.38%
More..
NASDAQ USA Top Gainers Stocks
LIWA 0.02 100.00%
VALV 0.06 100.00%
LOCM 0.09 50.00%
APPY 4.40 46.67%
TWER 0.30 36.36%
MEMP 0.70 34.62%
MYRX 0.04 33.33%
SCHS 0.12 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
AMCF 0.06 -60.00%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
RITT 0.06 -45.45%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX)

SOMX Technical Analysis 2
As on 6th Mar 2013 SOMX Share Price closed @ 3.00 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 1.19 & Sell for SHORT-TERM with Stoploss of 3.00 we also expect STOCK to react on Following IMPORTANT LEVELS.
SOMX Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
SOMX Other Details
Segment EQ
Market Capital 10500081.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
SOMX Address
SOMX
N/A
SOMX Latest News
Interactive Technical Analysis Chart Somaxon Pharmaceuticals, Inc. ( SOMX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Somaxon Pharmaceuticals, Inc.
SOMX Business Profile
Pernix Sleep Inc, formerly Somaxon Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of branded products and late-stage product candidates. The Company operates in one segment, which is the development and commercialization of pharmaceutical products. The Company�s focus is on commercial activities relating to Silenor. As of December 31, 2011, the clinical development program for Silenor included four Phase III clinical trials. In June 2011, it entered into agreements with Paladin Labs Inc. (Paladin), under which Paladin had the right to commercialize Silenor in Canada, South America, the Caribbean and Africa, subject to the receipt of marketing approval in each such territory. In March 2013, Pernix Therapeutics Holdings Inc acquired the Company.